valoctocogene roxaparvovec

AXP000252.1 · Viral vector gene therapy

Platform
AAV5 vector
Targets
F8
Originator
BioMarin Pharmaceutical
Sponsor
BioMarin Pharmaceutical

Names

NameTypeSource
valoctocogene roxaparvovecpreferred namecurator
Roctavianbrandfda
BMN 270former codecurator

Virus

Role
In vivo gene transfer
Family
Parvoviridae
Virus
adeno-associated virus 5
Strain
AAV5
Replication
non replicating
Modifications
liver-selective promoter
Transgenes
F8 (B-domain deleted)
Route
intravenous
Source
evidence

Approvals

AgencyRegionDateStatusBrandIndicationSource
EMAEU2022-08-24conditionalRoctavianSevere haemophilia A in adults without a history of factor VIII inhibitors and without detectable anti-AAV5 antibodiessource
FDAUS2023-06-29approvedRoctavianAdults with severe haemophilia A (factor VIII activity below 1 IU/dL)source

Clinical trials (7)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06224907Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia AActive not recruitingPhase 32023-12-252025-04-166Hemophilia A
NCT04684940Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior InhibitorsCompletedPhase 1/22020-12-102026-04-2010Hemophilia A With Anti Factor VIII; Hemophilia A With Inhibitor
NCT04323098Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia ACompletedPhase 32020-12-082023-01-2722Hemophilia A
NCT03520712Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5TerminatedPhase 1/22018-04-242024-08-073Blood Disorder; Clotting Disorders; Gene Therapy; Hemophilia A
NCT03392974Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kgCompletedPhase 32018-03-142019-05-221Hemophilia A
NCT03370913Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)CompletedPhase 32017-12-192020-11-16144Hemophilia A
NCT02576795Gene Therapy Study in Severe Haemophilia A Patients (270-201)CompletedPhase 1/22015-09-282024-02-1415Severe Haemophilia A
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT05768386A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)Enrolling by invitation2023-01-012040-01172Hemophilia Aname in title: BMN 270

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41818413Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels.Haemophilia : the official journal of the World Federation of Hemophilia2026name in title: valoctocogene roxaparvovec
PMID 41968461Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A.Haemophilia : the official journal of the World Federation of Hemophilia2026name in title: valoctocogene roxaparvovec
PMID 42064204Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results.Research and practice in thrombosis and haemostasis2026name in title: valoctocogene roxaparvovec
PMID 39800255Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study.Journal of thrombosis and haemostasis : JTH2025name in title: valoctocogene roxaparvovec
PMID 40986187Estimated Long-Term Durability of Valoctocogene Roxaparvovec Treatment in Male patients with Severe Hemophilia A: An Extrapolation of Clinical Data.Advances in therapy2025cited by trial NCT02576795
PMID 38317480Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment.Haemophilia : the official journal of the World Federation of Hemophilia2024name in title: valoctocogene roxaparvovec
PMID 38614387Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.Journal of thrombosis and haemostasis : JTH2024name in title: valoctocogene roxaparvovec
PMID 38616241Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.Advances in therapy2024cited by trial NCT03370913
PMID 38796703Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A.Molecular therapy : the journal of the American Society of Gene Therapy2024name in title: valoctocogene roxaparvovec
PMID 38975624Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A.Haemophilia : the official journal of the World Federation of Hemophilia2024cited by trial NCT02576795
PMID 39024543Blood biodistribution and vector shedding of valoctocogene roxaparvovec in people with severe hemophilia A.Blood advances2024cited by trial NCT03370913
PMID 36812433Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.The New England journal of medicine2023cited by trial NCT03370913
PMID 37678546Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1.Journal of thrombosis and haemostasis : JTH2023name in title: valoctocogene roxaparvovec
PMID 35294811Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.The New England journal of medicine2022cited by trial NCT03370913
PMID 35411075Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A.Nature medicine2022cited by trial NCT02576795
PMID 35879931Psychometric Validation of the Haemo-QOL-A in Participants with Hemophilia A Treated with Gene Therapy.Patient related outcome measures2022cited by trial NCT02576795
PMID 34378280Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.Haemophilia : the official journal of the World Federation of Hemophilia2021cited by trial NCT02576795
PMID 31893514Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.The New England journal of medicine2020cited by trial NCT02576795
PMID 32915950Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy.Blood2020cited by trial NCT02576795
PMID 29224506AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.The New England journal of medicine2017cited by trial NCT02576795

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 40785174A Paradigm Shift in Hemophilia Care: The Promise of Gene Therapy.Current gene therapy2026name in abstract: valoctocogene roxaparvovec
PMID 41198051Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy.Blood2026name in abstract: valoctocogene roxaparvovec
PMID 41274843Long-term durability of rAAV gene therapy in hemophilia: Factor expression, clinical outcomes and underlying molecular mechanisms.Blood reviews2026name in abstract: valoctocogene roxaparvovec
PMID 41448545Overview of gene therapy for hemophilia: questions and answers to navigate the innovation.Journal of thrombosis and haemostasis : JTH2026name in abstract: valoctocogene roxaparvovec
PMID 41549917Balancing Promise and Peril: Hemophilia Gene Therapy Insights.IUBMB life2026name in abstract: valoctocogene roxaparvovec
PMID 41709782Gene therapy in the treatment of hemophilia A: a systematic review and meta-analysis.Expert review of hematology2026name in abstract: valoctocogene roxaparvovec
PMID 41773269Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders.Journal of blood medicine2026name in abstract: valoctocogene roxaparvovec
PMID 41988906Bringing Gene Therapy Into Real World Clinical Practice.Haemophilia : the official journal of the World Federation of Hemophilia2026name in abstract: valoctocogene roxaparvovec
PMID 42049028From early promise to market withdrawal of valoctocogene roxaparvovec.Molecular therapy : the journal of the American Society of Gene Therapy2026name in title: valoctocogene roxaparvovec
PMID 42061679Correlation between Factor VIII chromogenic activity and antigen levels in patients treated with adeno-associated virus 5-mediated gene therapy for hemophilia A.Journal of thrombosis and haemostasis : JTH2026name in abstract: valoctocogene roxaparvovec
PMID 42232249Real-world provider experiences with hemophilia A gene therapy: administration of valoctocogene roxaparvovec.Research and practice in thrombosis and haemostasis2026name in title: valoctocogene roxaparvovec
PMID 42290228Italian Patients Journey for Gene Therapy in Haemophilia A.Haemophilia : the official journal of the World Federation of Hemophilia2026name in abstract: valoctocogene roxaparvovec
PMID 42389809Biopsy-proven immune-mediated hepatitis after valoctocogene roxaparvovec.Haematologica2026name in title: valoctocogene roxaparvovec
PMID 42432779Vulnerability, protection and fairness: ethical and regulatory limits in small-N gene therapy trials.Trials2026name in abstract: Roctavian
PMID 42662499Roctavian withdrawal: exploring the gap between innovation and healthcare system readiness in hemophilia A gene therapy.Research and practice in thrombosis and haemostasis2026name in title: Roctavian
PMID 42676001Bridging the Gap: A Systematic Review of Modern Hemophilia Therapies and Global Inequities in Clinical Trial Participation.Haemophilia : the official journal of the World Federation of Hemophilia2026name in abstract: valoctocogene roxaparvovec
PMID 42784360Impact of Gene Therapy on the Haemophilia-Free Mind: Outcomes Before and After Valoctocogene Roxaparvovec in GENEr8-1 Trial Participants.Haemophilia : the official journal of the World Federation of Hemophilia2026name in title: valoctocogene roxaparvovec
PMID 42947409Arthroplasty After Hemophilia Gene Therapy: Perioperative Implications and Clinical Experience.Haemophilia : the official journal of the World Federation of Hemophilia2026name in abstract: valoctocogene roxaparvovec
PMID 42976908Patient-Relevant Questions on Gene Therapy for Haemophilia.Hamostaseologie2026name in abstract: valoctocogene roxaparvovec
PMID 38588706Gene Therapy in Hemophilia A: Achievements, Challenges, and Perspectives.Seminars in thrombosis and hemostasis2025name in abstract: valoctocogene roxaparvovec
PMID 40090623Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance.Journal of thrombosis and haemostasis : JTH2025name in title: valoctocogene roxaparvovec
PMID 40091689A plain language summary on indirectly comparing bleeding after valoctocogene roxaparvovec gene therapy to bleeding with emicizumab prophylaxis.Expert review of hematology2025name in title: valoctocogene roxaparvovec
PMID 40156191The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy2025name in abstract: Roctavian
PMID 40464094Recombinant Adeno-Associated Virus Integration Profiles in Nonhuman Primates and Gene Therapy Participants after Treatment with Valoctocogene Roxaparvovec.Human gene therapy2025name in title: valoctocogene roxaparvovec
PMID 40488175Gene-based therapies for hemophilia.Research and practice in thrombosis and haemostasis2025name in abstract: valoctocogene roxaparvovec
PMID 40868273Curative Therapies for Hemophilias and Hemoglobinopathies in Adults: Immune, Gene, and Stem Cell Approaches in a Global Context.Biomedicines2025name in abstract: Roctavian
PMID 40916408Advances in Gene Therapy Clinical Trials for Hemophilia Care.Current gene therapy2025name in abstract: valoctocogene roxaparvovec
PMID 40924278Comparative Effectiveness of Valoctocogene Roxaparvovec and Efanesoctocog Alfa in the Treatment of Severe Hemophilia A: A Matching-Adjusted Indirect Comparison of Bleeding Frequency.Advances in therapy2025name in title: valoctocogene roxaparvovec
PMID 41127589Cost-effectiveness of emicizumab for the treatment of hemophilia A: a systematic review.Frontiers in public health2025name in abstract: valoctocogene roxaparvovec
PMID 41348030Deconstructing gene therapy in hemophilia for the clinician.Hematology. American Society of Hematology. Education Program2025name in abstract: valoctocogene roxaparvovec
PMID 41362291Nonclinical toxicity study duration in AAV gene therapy development: Evidence from industry survey supports adequacy of short-term assessments.Molecular therapy. Methods & clinical development2025name in abstract: Roctavian
PMID 37978816Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B.The Annals of pharmacotherapy2024name in title: valoctocogene roxaparvovec
PMID 37989969Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid.PharmacoEconomics2024name in abstract: valoctocogene roxaparvovec
PMID 38684460Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A.Haemophilia : the official journal of the World Federation of Hemophilia2024name in title: valoctocogene roxaparvovec
PMID 38764998Valoctocogene Roxaparvovec.Hospital pharmacy2024name in title: valoctocogene roxaparvovec
PMID 38845160Evaluation of one-stage and chromogenic assays for the laboratory measurement of factor VIII activity following valoctocogene roxaparvovec infusion.Haemophilia : the official journal of the World Federation of Hemophilia2024name in title: valoctocogene roxaparvovec
PMID 38991118Roctavian gene therapy for hemophilia A.Blood advances2024name in title: Roctavian
PMID 39104575The longitudinal kinetics of AAV5 vector integration profiles and evaluation of clonal expansion in mice.Molecular therapy. Methods & clinical development2024name in abstract: valoctocogene roxaparvovec
PMID 39136120Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real-world clinical experience.Haemophilia : the official journal of the World Federation of Hemophilia2024name in title: valoctocogene roxaparvovec
PMID 39226466Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice.Blood advances2024name in title: valoctocogene roxaparvovec
PMID 39242221[Marketing authorisation for rare diseases: The European regulatory perspective using the example of gene and cell therapies].Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen2024name in abstract: Roctavian
PMID 39321118A systematic review of cost-effectiveness analyses of gene therapy for hemophilia type A and B.Journal of managed care & specialty pharmacy2024name in abstract: valoctocogene roxaparvovec
PMID 39339243Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B.Pharmaceutics2024name in abstract: valoctocogene roxaparvovec
PMID 39687929Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial.Research and practice in thrombosis and haemostasis2024name in title: valoctocogene roxaparvovec
PMID 39712873Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GENEr8-1 phase III trial.Therapeutic advances in hematology2024name in abstract: valoctocogene roxaparvovec
PMID 35132205Lack of germline transmission in male mice following a single intravenous administration of AAV5-hFVIII-SQ gene therapy.Gene therapy2023name in abstract: valoctocogene roxaparvovec
PMID 36696462Valoctocogene roxaparvovec gene transfer in participants with HIV.Blood advances2023name in title: valoctocogene roxaparvovec
PMID 37347645Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.Haemophilia : the official journal of the World Federation of Hemophilia2023name in title: valoctocogene roxaparvovec
PMID 37353081Hemophilia gene therapy: first, do no harm.Journal of thrombosis and haemostasis : JTH2023name in abstract: valoctocogene roxaparvovec
PMID 37490225Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2023name in abstract: valoctocogene roxaparvovec
PMID 37590493BioMarin's ROCTAVIAN Wins Food and Drug Administration Approval As First Gene Therapy for Severe Hemophilia A.Human gene therapy2023name in title: Roctavian
PMID 37672530Hemophilia Gene Therapy: The End of the Beginning?Human gene therapy2023name in abstract: valoctocogene roxaparvovec
PMID 37755692Valoctocogene roxaparvovec (Roctavian) - a gene therapy for severe hemophilia A.The Medical letter on drugs and therapeutics2023name in title: valoctocogene roxaparvovec
PMID 38462459Viral Vectors in Gene Replacement Therapy.Biochemistry. Biokhimiia2023name in abstract: Roctavian
PMID 34421119Ultra-sensitive AAV capsid detection by immunocapture-based qPCR following factor VIII gene transfer.Gene therapy2022name in abstract: valoctocogene roxaparvovec
PMID 35036471Molecular analysis of AAV5-hFVIII-SQ vector-genome-processing kinetics in transduced mouse and nonhuman primate livers.Molecular therapy. Methods & clinical development2022name in abstract: valoctocogene roxaparvovec
PMID 35141470Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A.HemaSphere2022name in abstract: valoctocogene roxaparvovec
PMID 35782594Application of in-vitro-cultured primary hepatocytes to evaluate species translatability and AAV transduction mechanisms of action.Molecular therapy. Methods & clinical development2022name in abstract: valoctocogene roxaparvovec
PMID 36082993Liver Gene Therapy.Human gene therapy2022name in abstract: valoctocogene roxaparvovec
PMID 36092364Young mice administered adult doses of AAV5-hFVIII-SQ achieve therapeutic factor VIII expression into adulthood.Molecular therapy. Methods & clinical development2022name in abstract: valoctocogene roxaparvovec
PMID 36142153The Arrival of Gene Therapy for Patients with Hemophilia A.International journal of molecular sciences2022name in abstract: valoctocogene roxaparvovec
PMID 36214970Valoctocogene Roxaparvovec: First Approval.Drugs2022name in title: valoctocogene roxaparvovec
PMID 36485127Gene therapy for hemophilia.Hematology. American Society of Hematology. Education Program2022name in abstract: valoctocogene roxaparvovec
PMID 39086961Strategies to improve safety profile of AAV vectors.Frontiers in molecular medicine2022name in abstract: Roctavian
PMID 33309883Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.Molecular therapy : the journal of the American Society of Gene Therapy2021name in title: valoctocogene roxaparvovec
PMID 33908280The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors.Journal of managed care & specialty pharmacy2021name in title: valoctocogene roxaparvovec
PMID 31890737Prednisolone Does Not Regulate Factor VIII Expression in Mice Receiving AAV5-hFVIII-SQ: Valoctocogene Roxaparvovec.Molecular therapy. Methods & clinical development2020name in title: valoctocogene roxaparvovec
PMID 31971453Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A.Journal of medical economics2020name in abstract: valoctocogene roxaparvovec
PMID 32775496Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter.Molecular therapy. Methods & clinical development2020name in abstract: valoctocogene roxaparvovec
PMID 31193016The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene Therapy.Molecular therapy. Methods & clinical development2019name in abstract: valoctocogene roxaparvovec
PMID 29292164Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice.Molecular therapy : the journal of the American Society of Gene Therapy2018name in title: BMN 270

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01HL177230Capsid- and genome-modified AAV3 vectors for hemophilia gene therapy.UNIVERSITY OF FLORIDASRIVASTAVA, ARUN2025–2026name in abstract: Roctavian
R43HL182565Development of AAV Episome-Based Nonviral Vectors for Prolonged Gene Expression in Hemophilia AM34 INCGRIEGER, JOSHUA2026–2026name in abstract: Roctavian
R21AI180416Studies of the KIAA0319L-mediated productive transduction pathways of rAAV vectorsUNIVERSITY OF KANSAS MEDICAL CENTERQIU, JIANMING2024–2025name in abstract: Roctavian

Notes

AAV5 vector carrying a B-domain-deleted factor VIII gene for severe haemophilia A, given as a single intravenous infusion. EU authorisation is conditional; the US label requires no factor VIII inhibitors and no detectable anti-AAV5 antibodies.

How to cite

valoctocogene roxaparvovec (AXP000252.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000252.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.